

Add the following new claims:

Sub 57 --23. A method for modulating an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 31-33.

24. The method of claim 23, wherein the immune response is enhanced.

Sub 58 25. A method for modulating an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of: sequences having at least 75% identity to a sequence of SEQ ID NO: 31-33, wherein the polypeptide has the same functional properties as a sequence of SEQ ID NO: 31-33.

26. The method of claim 25, wherein the immune response is enhanced.

27. A method for modulating an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of: sequences having at least 90% identity to a sequence of SEQ ID NO: 31-33, wherein the polypeptide has the same functional properties as a sequence of SEQ ID NO: 31-33.

28. The method of claim 27, wherein the immune response is enhanced.--

#### REMARKS

In response to the Restriction Requirement mailed December 31, 2001, applicants hereby elect the invention of claim 22 and the species of SEQ ID NO: 31-33. SEQ ID NO: 31 is the amino acid sequence for a murine fibroblast growth factor receptor, referred to as FGFR5. The amino acid sequence for the human FGFR5 homologue is provided in SEQ ID NO: 33 (see Example 4, page 23, lines 9-17, of the specification). As described in Example 3 (page 22, line 15 - page 23, line 2) of the specification, SEQ ID NO: 32 represents a splice variant of the sequence of SEQ ID NO: 31. Applicants believe the sequences of SEQ ID NO: 31, 32 and 33 are likely to have similar functional properties.

It is submitted that, due to relationship between the sequences, examination of the three sequences of SEQ ID NO: 31, 32 and 33 would not constitute an unreasonable burden and applicants therefore request that these three sequences be examined. In the event that the applicants continue to be restricted to a single species, they request that the species of SEQ ID NO: 33 be examined at this time.